Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 30 11:24AM ET
1.00
Dollar change
-0.01
Percentage change
-0.99
%
Index- P/E- EPS (ttm)-0.73 Insider Own11.49% Shs Outstand227.17M Perf Week-4.76%
Market Cap255.50M Forward P/E- EPS next Y-0.69 Insider Trans-0.56% Shs Float226.14M Perf Month-15.97%
Income-163.60M PEG- EPS next Q-0.17 Inst Own52.00% Short Float1.52% Perf Quarter-36.31%
Sales18.33M P/S13.94 EPS this Y-682.22% Inst Trans-0.50% Short Ratio2.50 Perf Half Y124.16%
Book/sh0.10 P/B10.48 EPS next Y1.63% ROA-59.92% Short Interest3.44M Perf Year-7.41%
Cash/sh0.56 P/C1.78 EPS next 5Y1.00% ROE-302.27% 52W Range0.42 - 2.05 Perf YTD26.10%
Dividend Est.- P/FCF- EPS past 5Y10.30% ROI-382.10% 52W High-51.22% Beta2.31
Dividend TTM- Quick Ratio2.81 Sales past 5Y134.88% Gross Margin40.99% 52W Low138.10% ATR (14)0.09
Dividend Ex-Date- Current Ratio2.81 EPS Y/Y TTM-4.33% Oper. Margin-1106.09% RSI (14)38.15 Volatility5.71% 8.27%
Employees449 Debt/Eq0.97 Sales Y/Y TTM-74.39% Profit Margin-892.51% Recom1.89 Target Price2.89
Option/ShortYes / Yes LT Debt/Eq0.76 EPS Q/Q-3280.95% Payout- Rel Volume0.73 Prev Close1.01
Sales Surprise-42.53% EPS Surprise80.35% Sales Q/Q-88.19% EarningsMay 15 BMO Avg Volume1.37M Price1.00
SMA20-10.91% SMA50-16.88% SMA2008.55% Trades Volume329,451 Change-0.99%
Date Action Analyst Rating Change Price Target Change
TodayInitiated Scotiabank Sector Outperform $3.15
Mar-24-23Initiated Bryan Garnier Buy $3.60
Jan-03-23Upgrade Guggenheim Neutral → Buy $5
Nov-09-22Upgrade Mizuho Neutral → Buy $9
May-28-21Initiated Barclays Underweight $4
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
May-17-24 06:49AM
May-16-24 08:18AM
May-15-24 12:53PM
11:07AM
07:30AM
07:00AM Loading…
07:00AM
May-01-24 12:00PM
Apr-23-24 07:45AM
Apr-15-24 02:12PM
Apr-12-24 08:00AM
05:37AM
Mar-27-24 07:30PM
Mar-07-24 01:42PM
08:24AM
Mar-06-24 12:52PM
07:00AM Loading…
07:00AM
Feb-27-24 08:00AM
Feb-21-24 04:00PM
Feb-16-24 03:57AM
Feb-13-24 06:15PM
Jan-31-24 04:44PM
Jan-30-24 01:02PM
Jan-16-24 11:17AM
Jan-04-24 07:37AM
Dec-06-23 07:00AM
Nov-30-23 10:52AM
Nov-29-23 08:00AM
Nov-13-23 09:35AM
08:35AM
Nov-08-23 07:30AM
07:05AM Loading…
07:05AM
Nov-07-23 06:15PM
Oct-31-23 08:00AM
08:00AM
Oct-27-23 06:15PM
Oct-25-23 08:06AM
Oct-23-23 04:15AM
Sep-11-23 08:00AM
Aug-09-23 07:29AM
Aug-03-23 01:24PM
Jul-28-23 12:30PM
Jul-20-23 07:28AM
Jul-16-23 08:18PM
Jun-29-23 09:18AM
Jun-26-23 11:23AM
11:15AM
Jun-23-23 09:15AM
Jun-22-23 09:40AM
Jun-19-23 10:18AM
Jun-16-23 08:39AM
Jun-15-23 09:43AM
08:18AM
Jun-13-23 10:14AM
Jun-12-23 10:00AM
09:48AM
Jun-09-23 10:52AM
Jun-06-23 06:50AM
Jun-05-23 11:40AM
10:22AM
Jun-01-23 03:29PM
May-30-23 09:35AM
May-25-23 05:00PM
May-12-23 07:29AM
May-09-23 06:43AM
May-05-23 05:00AM
Apr-28-23 12:00PM
Apr-18-23 11:49AM
Apr-12-23 10:42AM
Apr-11-23 12:13PM
08:00AM
Mar-08-23 07:14AM
05:23AM
Mar-06-23 01:08PM
06:30AM
06:00AM
Feb-22-23 08:00AM
Feb-16-23 08:00AM
Jan-09-23 08:00AM
Jan-08-23 07:06AM
Dec-28-22 06:51AM
Dec-27-22 09:05AM
Dec-23-22 01:20PM
Dec-10-22 09:02AM
Nov-18-22 08:00AM
Nov-13-22 07:28AM
Nov-11-22 10:52AM
Nov-10-22 06:03AM
Nov-08-22 03:11PM
09:41AM
07:30AM
07:00AM
Oct-27-22 12:27PM
Oct-25-22 11:12AM
08:00AM
Sep-09-22 10:23AM
07:00AM
Aug-25-22 08:00AM
Aug-10-22 06:27AM
Aug-04-22 07:30AM
Aug-01-22 06:21AM
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rawcliffe AdrianChief Executive OfficerJan 17 '24Sale0.6730,08020,24444,848Jan 17 05:31 PM
Bertrand William C JRChief Operating OfficerJan 17 '24Sale0.6718,90812,7257,785Jan 17 05:30 PM
Norry ElliotChief Medical OfficerJan 17 '24Sale0.6718,27612,3007,785Jan 17 05:31 PM
Lunger JohnChief Patient Supply OfficerJan 17 '24Sale0.6718,11412,1917,785Jan 17 05:30 PM
Rawcliffe AdrianChief Executive OfficerJan 16 '24Sale0.799,3047,35014,104Jan 17 05:31 PM
Lunger JohnChief Patient Supply OfficerJan 16 '24Sale0.794,6813,6987,023Jan 17 05:30 PM
Bertrand William C JRChief Operating OfficerJan 16 '24Sale0.794,6813,6987,023Jan 17 05:30 PM
Norry ElliotChief Medical OfficerJan 16 '24Sale0.792,2871,8073,363Jan 17 05:31 PM
Rawcliffe AdrianChief Executive OfficerJan 12 '24Sale0.8517,25714,73926,388Jan 12 05:00 PM
Norry ElliotChief Medical OfficerJan 12 '24Sale0.857,7996,66111,841Jan 12 05:00 PM
Bertrand William C JRChief Operating OfficerJan 12 '24Sale0.855,2204,4587,874Jan 12 05:00 PM
Lunger JohnChief Patient Supply OfficerJan 12 '24Sale0.855,2204,4587,874Jan 12 05:00 PM
Rawcliffe AdrianChief Executive OfficerJan 11 '24Sale0.8411,9459,99418,395Jan 12 05:00 PM
Lunger JohnChief Patient Supply OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Bertrand William C JRChief Operating OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Norry ElliotChief Medical OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Rawcliffe AdrianChief Executive OfficerSep 01 '23Sale0.782,4031,8743,449Sep 01 07:00 PM
Lunger JohnChief Patient Supply OfficerAug 01 '23Sale0.913,0962,8044,718Aug 01 05:00 PM
Menzel Garry EDirectorJul 10 '23Sale0.9147,70243,44775,056Jul 10 05:01 PM
Rawcliffe AdrianChief Executive OfficerJun 27 '23Sale0.922,3332,1463,519Jun 27 09:15 PM